Market Overview

Sunrun Q4 Earnings Preview


Sunrun (NASDAQ: RUN) unveils its next round of earnings Tuesday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement

Earnings and Revenue

Sunrun earnings will be near 39 cents per share on sales of $136.18 million, according to analysts.

In the same quarter last year, Sunrun reported earnings per share of 27 cents per share on revenue of $120.58 million. If the company were to match the consensus estimate when it reports Tuesday, EPS would be up 44.44 percent. Sales would be up 12.93 percent from the same quarter last year.

Here's how the company's reported EPS has stacked up against analyst estimates in the past:


Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate 0.31 0.31 0.17 0.05
EPS Actual 0.25 0.23 0.12 0.27


Stock Performance

Over the last 52-week period, shares are up 28.83 percent. Given that these returns are generally positive, long-term shareholders can relax going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.

Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. The popular rating by analysts on Sunrun stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Conference Call

Sunrun's Q4 conference call is scheduled to begin at 5:00 p.m. ET and can be accessed here.

Posted-In: Earnings News Previews Trading Ideas


Related Articles (RUN)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

25 Stocks Moving In Tuesday's Pre-Market Session

PTC Therapeutics Q4 Earnings Preview